JP7710450B2 - Ｆｃ変異を有するヘテロダイマータンパク質 - Google Patents

Ｆｃ変異を有するヘテロダイマータンパク質

Info

Publication number
JP7710450B2
JP7710450B2 JP2022544309A JP2022544309A JP7710450B2 JP 7710450 B2 JP7710450 B2 JP 7710450B2 JP 2022544309 A JP2022544309 A JP 2022544309A JP 2022544309 A JP2022544309 A JP 2022544309A JP 7710450 B2 JP7710450 B2 JP 7710450B2
Authority
JP
Japan
Prior art keywords
domain
substitutions
amino acid
substitution
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022544309A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023511376A (ja
JP2023511376A5 (https=
JPWO2021148006A5 (https=
Inventor
ピーター， ペイチー ルオ，
ファンヨン トゥー，
ギジョン リュウ，
チョンシー タイ，
チエンフォン シー，
チーシオン リン，
ヤン リー，
Original Assignee
アダジーン アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アダジーン アーゲー filed Critical アダジーン アーゲー
Publication of JP2023511376A publication Critical patent/JP2023511376A/ja
Publication of JP2023511376A5 publication Critical patent/JP2023511376A5/ja
Publication of JPWO2021148006A5 publication Critical patent/JPWO2021148006A5/ja
Priority to JP2025114854A priority Critical patent/JP2025160226A/ja
Application granted granted Critical
Publication of JP7710450B2 publication Critical patent/JP7710450B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022544309A 2020-01-23 2021-01-22 Ｆｃ変異を有するヘテロダイマータンパク質 Active JP7710450B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025114854A JP2025160226A (ja) 2020-01-23 2025-07-08 Ｆｃ変異を有するヘテロダイマータンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/073960 2020-01-23
CN2020073960 2020-01-23
PCT/CN2021/073347 WO2021148006A1 (en) 2020-01-23 2021-01-22 Heterodimeric proteins with fc mutations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025114854A Division JP2025160226A (ja) 2020-01-23 2025-07-08 Ｆｃ変異を有するヘテロダイマータンパク質

Publications (4)

Publication Number Publication Date
JP2023511376A JP2023511376A (ja) 2023-03-17
JP2023511376A5 JP2023511376A5 (https=) 2025-04-21
JPWO2021148006A5 JPWO2021148006A5 (https=) 2025-04-21
JP7710450B2 true JP7710450B2 (ja) 2025-07-18

Family

ID=76992067

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022544309A Active JP7710450B2 (ja) 2020-01-23 2021-01-22 Ｆｃ変異を有するヘテロダイマータンパク質
JP2025114854A Pending JP2025160226A (ja) 2020-01-23 2025-07-08 Ｆｃ変異を有するヘテロダイマータンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025114854A Pending JP2025160226A (ja) 2020-01-23 2025-07-08 Ｆｃ変異を有するヘテロダイマータンパク質

Country Status (11)

Country Link
US (1) US20230124669A1 (https=)
EP (1) EP4093778A4 (https=)
JP (2) JP7710450B2 (https=)
KR (1) KR20220145833A (https=)
CN (1) CN115279796A (https=)
AU (1) AU2021210482A1 (https=)
BR (1) BR112022014574A2 (https=)
CA (1) CA3165045A1 (https=)
IL (1) IL294878A (https=)
MX (1) MX2022009101A (https=)
WO (1) WO2021148006A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022170619A1 (en) * 2021-02-11 2022-08-18 Adagene Pte. Ltd. Anti-cd3 antibodies and methods of use thereof
EP4405398A4 (en) * 2021-09-21 2025-10-29 Qilu Puget Sound Biotherapeutics Corp FC HETERODIMERS ALLOWING THE MANUFACTURE OF FUSION PROTEINS AND BI-SPECIFIC ANTIBODIES
WO2023183888A1 (en) * 2022-03-23 2023-09-28 Cytomx Therapeutics, Inc. Activatable antigen-binding protein constructs and uses of the same
WO2023193239A1 (en) 2022-04-08 2023-10-12 Peter Peizhi Luo Anti-cd28 antibodies and methods of use thereof
AU2024287529A1 (en) * 2023-07-10 2026-02-05 Regeneron Pharmaceuticals, Inc. Bispecific pd-l1x4-1bb antibodies and methods of use thereof
WO2025108310A1 (zh) * 2023-11-20 2025-05-30 江苏恒瑞医药股份有限公司 通过重组反应制备异源多聚体的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019502701A (ja) 2015-12-16 2019-01-31 蘇州康寧傑瑞生物科技有限公司 Ｃｈ３ドメインに基づくヘテロダイマー分子、その調製方法及び用途
WO2019126576A1 (en) 2017-12-21 2019-06-27 Amunix Pharmaceuticals, Inc. Release segments and binding compositions comprising same
WO2019149282A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Activatable antibodies and methods of making and using thereof
JP2019530641A (ja) 2016-07-19 2019-10-24 アイベントラス・インコーポレイテッドＩｂｅｎｔｒｕｓ，Ｉｎｃ． 二重特異性タンパク質およびその製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101270829B1 (ko) * 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
US8054928B2 (en) * 2005-11-14 2011-11-08 Ati Technologies, Inc. Programmable preamble system and method
US20100189651A1 (en) * 2009-01-12 2010-07-29 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
US9493578B2 (en) * 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CN102958942A (zh) * 2009-12-29 2013-03-06 新兴产品开发西雅图有限公司 异二聚体结合蛋白及其应用
CN114805583A (zh) * 2010-05-27 2022-07-29 根马布股份公司 针对her2的单克隆抗体
US10344050B2 (en) * 2011-10-27 2019-07-09 Genmab A/S Production of heterodimeric proteins
WO2013118722A1 (ja) * 2012-02-06 2013-08-15 トヨタ自動車株式会社 硫化物固体電解質材料、電池および硫化物固体電解質材料の製造方法
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
CA2902739C (en) * 2013-03-15 2022-11-22 Xencor, Inc. Heterodimeric proteins
CN110627907B (zh) * 2013-11-04 2024-03-29 艾科诺斯科技股份有限公司 重靶向t细胞的异源二聚免疫球蛋白的产生
US20160176969A1 (en) * 2014-11-26 2016-06-23 Xencor, Inc. Heterodimeric antibodies including binding to cd8
CN107001482B (zh) * 2014-12-03 2021-06-15 豪夫迈·罗氏有限公司 多特异性抗体
WO2016152136A1 (ja) * 2015-03-20 2016-09-29 日本電気株式会社 プラガブル光モジュール、光通信システム及びプラガブル光モジュールの制御方法
WO2019014912A1 (zh) * 2017-07-21 2019-01-24 赵磊 一种异二聚体蛋白及其制备方法
TWI798601B (zh) * 2020-11-27 2023-04-11 晶睿通訊股份有限公司 地面起伏偵測方法及其監控攝影機
JP7295438B2 (ja) * 2020-11-30 2023-06-21 日亜化学工業株式会社 面状光源
WO2023193239A1 (en) * 2022-04-08 2023-10-12 Peter Peizhi Luo Anti-cd28 antibodies and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019502701A (ja) 2015-12-16 2019-01-31 蘇州康寧傑瑞生物科技有限公司 Ｃｈ３ドメインに基づくヘテロダイマー分子、その調製方法及び用途
JP2019530641A (ja) 2016-07-19 2019-10-24 アイベントラス・インコーポレイテッドＩｂｅｎｔｒｕｓ，Ｉｎｃ． 二重特異性タンパク質およびその製造方法
WO2019126576A1 (en) 2017-12-21 2019-06-27 Amunix Pharmaceuticals, Inc. Release segments and binding compositions comprising same
WO2019149282A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Activatable antibodies and methods of making and using thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Methods，2014年，Vol. 65，p. 77-94
Nature Biotechnology，1998年，Vol. 16，p. 677-681
The Journal of Biological Chemistry，2010年，Vol. 285，p. 19637-19646

Also Published As

Publication number Publication date
IL294878A (en) 2022-09-01
CN115279796A (zh) 2022-11-01
CA3165045A1 (en) 2021-07-29
TW202140570A (zh) 2021-11-01
EP4093778A1 (en) 2022-11-30
JP2023511376A (ja) 2023-03-17
JP2025160226A (ja) 2025-10-22
WO2021148006A9 (en) 2025-02-13
WO2021148006A1 (en) 2021-07-29
KR20220145833A (ko) 2022-10-31
AU2021210482A1 (en) 2022-08-25
MX2022009101A (es) 2022-10-07
US20230124669A1 (en) 2023-04-20
BR112022014574A2 (pt) 2022-09-27
EP4093778A4 (en) 2024-07-10

Similar Documents

Publication Publication Date Title
JP7710450B2 (ja) Ｆｃ変異を有するヘテロダイマータンパク質
US20250326860A1 (en) Anti-cd3 antibodies and methods of use thereof
JP7611820B2 (ja) Ｄｌｌ３シングルドメイン抗体およびその治療用組成物
CN112771066B (zh) 可活化抗体及其制备和使用方法
US20240150464A1 (en) Materials and methods for modulating t cell mediated immunity
JP2022512684A (ja) Ｂ７ｈ３シングルドメイン抗体およびその治療用組成物
US20250257133A1 (en) Anti-CD28 Antibodies and Methods of Use Thereof
CN119137159A (zh) 抗cd137抗体和其制备和使用方法
TWI920054B (zh) 具有Ｆｃ突變之異二聚蛋白質
JP7691138B2 (ja) ４－１ｂｂおよび０ｘ４０結合タンパク質ならびに関連する組成物および方法、４－１ｂｂに対する抗体、０ｘ４０に対する抗体
JP2023551907A (ja) 腫瘍関連抗原及びｃｄ３結合タンパク質、関連する組成物、及び方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240122

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250114

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20250411

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250610

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250708

R150 Certificate of patent or registration of utility model

Ref document number: 7710450

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150